Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer

Anticancer Research

Volumn 27, Issue 4 C, 2007, Pages 2641-2648

  Miyoshi, Takanori ^a   Kondo, Kazuya ^a   Toba, Hiroaki ^a   Yoshida, Mitsuteru ^a   Fujino, Haruhiko ^a   Kenzaki, Koichiro ^a   Sakiyama, Shoji ^a   Takehisa, Masatsugu ^b   Tangoku, Akira ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b Yoshinogawa   (Japan)

Author keywords

Dihydropyrimidine dehydrogenase (DPD); Non small cell lung cancer; Thymidylate synthase (TS)

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; THYMIDYLATE SYNTHASE; UFT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; POSTOPERATIVE CARE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; NEOPLASM STAGING; TEGAFUR; THYMIDYLATE SYNTHASE; URACIL;

EID: 34547788914     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Hoffman PC, Mauer AM and Vokes EE: Lung cancer. Lancet 355: 479-485, 2000.
2. Mountain CF: Revisions in the international system for staging lung cancer. Chest 111: 1710-1714, 1997.
3. Naruke T, Tsuchiya R, Kondo H and Asamura H: Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. Ann Thorac Surg 71: 1759-1764, 2001.
4. Matsuoka H, Ueo H, Sugimachi K and Akiyoshi T: Preliminary evidence that incorporation of 5-fluorouracil into RNA correlates with antitumor response. Cancer Invest 10: 265-269, 1992.
5. Diasio RB and Harris BE: Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16: 215-237, 1989.
6. Beck A, Etienne MC, Cheradame S, Fischel JL, Formento P, Renee N and Milano G: A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 30: 1517-1522, 1994.
7. Kirihara Y, Yamamoto W, Toge T and Nishiyama M: Dihydropyrimidine dehydrogenase, multidrug resistance-associated protein, and thymidylate synthase gene expression levels can predict 5-fluorouracil resistance in human gastrointestinal cancer cells. Int J Oncol 14: 551-556, 1999.
8. Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, Takechi T, Okabe H, Fukushima M and Kitajima M: Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil. Jpn J Cancer Res 91: 105-112, 2000.
9. Oguri T, Achiwa H, Bessho Y, Muramatsu H, Maeda H, Niimi T, Sato S and Ueda R: The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells. Lung Cancer 49: 345-51, 2005.
10. Etienne MC, Cheradame S, Fischel JL, Formento P, Dassonville O, Renee N, Schneider M, Thyss A, Demard F and Milano G: Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13: 1663-1670, 1995.
11. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB and Danenberg PV: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6: 1322-1327, 2000.
12. Huang CL, Yokomise H, Kobayashi S, Fukushima M, Hitomi S and Wada H: Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy. Int J Oncol 17: 47-54, 2000.
13. Wada H, Hitomi S and Teramatsu T: Adjuvant chemotherapy after complete resection in non-small cell lung cancer. West Japan Study Group for Lung Cancer Surgery. J Clin Oncol 14: 1048-1054, 1996.
14. Wada H, Miyahara R, Tanaka F and Hitomi S: Postoperative adjuvant chemotherapy with PVM (cisplatin + vindesin + mitomycin C) and UFT (uracil + tegafur) in resected stage I-II NSCLC (non-small cell lung cancer). Eur J Cardiothorac Surg 15: 438-443, 1999.
15. Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan): A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study). Eur J Surg Oncol 21: 69-77, 1995.
16. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N and Ohta M; Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy: A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350: 1713-1721, 2004.
17. World Health Organization: Histological typing of lung tumors. Am J Clin Pathol 77: 123-136, 1982.
18. Nakagawa T, Tanaka F, Otake Y, Yanagihara K, Miyahara R, Matsuoka K, Takata T, Yamada T, Fukushima M and Wada H: Prognostic value of thymidylate synthase expression in patients with p-stage I adenocarcinoma of the lung. Lung Cancer 35: 165-170, 2002.
19. Okabe K, Tsujimoto H and Fukushima M: Preparation of the antibodies against recombinant human thymidylate synthase for the detection of its intratumoral levels and the application to sensitivity-study of 5-fluorouracil. Oncol Rep 17: 2728-2736, 1997.
20. Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, Takechi T, Okabe H, Fukushima M and Kitajima M: Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil. Jpn J Cancer Res 91: 105-112, 2000.
21. Nakagawa T, Tanaka F, Takata T, Matsuoka K, Miyahara R, Otake Y, Yanagihara K, Fukushimab M and Wada H: Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur + uracil) in patients with p-Stage I non-small cell lung cancer. J Surg Oncol 81: 87-92, 2002.
22. Miyoshi T, Kondo K, Fujino H, Takahashi Y, Sawada N, Sakiyama S, Tsuyuguchi M, Kimura S, Sumitomo M and Monden Y: Thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer: relationship between mRNA expression and activity. Anticancer Res 25: 923-930, 2005.
23. Samsonoff WA, Reston J, McKee M, O'Connor B, Galivan J, Maley G and Maley F: Intracellular location of thymidylate synthase and its state of phosphorylation. J Biol Chem 272: 13281-13285, 1997.
24. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV and Leichman L: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55: 1407-1412, 1995.
25. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M and Danenberg PV: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15: 3223-3229, 1997.
26. Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Garcia Y, Li J and Leichman L: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 14: 176-182, 1996.
27. Zhang ZG, Harstrick A and Rustum YM: Mechanisms of resistance to fluoropyrimidines. Semin Oncol 19: 4-9, 1992.
28. Johnston PG, Drake JC, Trepel J and Allegra CJ: Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 52: 4306-4312, 1992.
29. Peters GJ, van der Wilt CL and van Groeningen CJ: Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase. Eur J Cancer 10: 1408-1411, 1994.
30. Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, Kitajima M, Takechi T, Okabe H and Fukushima M: Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice. Clin Cancer Res 5: 883-889, 1999.
31. Terashima M, Irinoda T, Fujiwara H, Nakaya T, Takagane A, Abe K, Yonezawa H, Oyama K, Inaba T, Saito K, Takechi T and Fukushima M: Role of thymidylate synthase and dihydropyrimidine dehydrogenase on tumor progression and sensitivity to 5-fluorouracil in human gastric cancer. Anticancer Res 22: 761-768, 2002.
32. Mirjolet JF, Barberi-Heyob M, Merlin JL, Marchal S, Etienne MC, Milano G and Bey P: Thymidylate synthase expression and activity: relation to S-phase parameters and 5-fluorouracil sensitivity. Br J Cancer 78: 62-68, 1998.
33. Fujiwara H, Terashima M, Irinoda T, Takagane A, Abe K, Kashiwaba M, Oyama K, Takahashi M, Maesawa C, Saito K, Takechi T and Fukushima M: Quantitative measurement of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level in gastric cancer by real-time RT-PCR. Jpn J Cancer Res 93: 1342-1350, 2002.